Over the past decade, melanoma has led the field in new cancer treatments, with impressive
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …

Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …

Uveal melanoma (UM) is a highly metastatic cancer that, in contrast to cutaneous
melanoma, is largely unresponsive to checkpoint immunotherapy. Here, we interrogate the …

Cancer stem cells (CSCs) are a population of self-renewal cells with high tumorigenic
potency. CSCs can adopt easily with changes in the nearby milieu, and are more resistant to …

Malignant melanoma is notorious for its inter-and intratumour heterogeneity, based on
transcriptionally distinct melanoma cell phenotypes. It is thought that these distinct …

Lineage plasticity has emerged as an important mechanism of treatment resistance in
prostate cancer. Treatment-refractory prostate cancers are increasingly associated with loss …

During tumor progression, cancer cells come into contact with various non-tumor cell types,
but it is unclear how tumors adapt to these new environments. Here, we integrate spatially …

Melanoma is an aggressive malignancy originating from pigment-producing melanocytes.
The development of targeted therapies (MAPK pathway inhibitors) and immunotherapies …